Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the ...

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Panelists discuss how thrombotic risk assessment—anchored in age, thrombotic history, and additional factors like leukocytosis and JAK2 allele burden—guides personalized therapy in polycythemia vera ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial ...

Incyte Corp (INCY) reports a 20% revenue increase, driven by strong Jakafi sales and a successful Niktimvo launch, while ...

Discover key insights from Incyte's Q1 2025 earnings: robust revenue growth, Jakafi success, new product launches, and pipeline updates driving ...

Blood cancers, a category that includes polycythemia vera (PV), are a risk factor for severe COVID-19. As such, managing your risk and taking steps to prevent COVID-19 if you have PV are important.

Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Kuykendall, M.D. (Moffitt Cancer Center) Title: Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV) Abstract: LBA3 ...

“Asher’s suggestion is ‘Little Dolly,’ and he is not straying away from that,” the proud father tells PEOPLE. Booko says he ...